NEW YORK (GenomeWeb News) – Empiriko will use Interchim's mass spectrometry-based technology to perform drug metabolism studies as part of a partnership between the companies announced today.

Under the terms of the deal, Empiriko will leverage Interchim's PuriFlash MassSpec technology to perform near real-time and cost-effective in vitro and ex vivo studies using Empiriko's Biomimiks technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.